Atossa Therapeutics, Inc.

As of November 14, 2016, Atossa Therapeutics, Inc. is considered overvalued with negative financial metrics, including a Price to Book Value of 1.78 and a ROCE of -2805.50%, indicating significant deterioration in its valuation outlook compared to peers.

As of April 23, 2025, the market trend is mildly bearish, influenced by mixed signals from daily and weekly indicators, with the daily moving averages and monthly MACD indicating bearishness, while the weekly MACD and Bollinger Bands show some bullishness.

As of March 2022, Atossa Therapeutics, Inc.'s management team includes Dr. Steven Quay as Chairman, President, and CEO, with Dr. Shu-Chih Chen on the Board and several Independent Directors: Dr. Stephen Galli, Mr. H. Lawrence Remmel, Mr. Richard Steinhart, and Mr. Gregory Weaver.

Atossa Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for breast cancer and related conditions. It has a market cap of approximately $104.69 million and reported a net loss of $7 million as of March 2025.

As of Jun 18, Atossa Therapeutics, Inc. has a market capitalization of 104.69 million and reported net sales of 0.00 million with a net profit of -26.35 million over the last four quarters. The balance sheet shows shareholder's funds of 71.48 million and total assets of 76.44 million.